[{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Sage Chemical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu Opoid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Sage Chemical","highestDevelopmentStatusID":"10","companyTruncated":"Harm Reduction Therapeutics \/ Sage Chemical"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Purdue Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Naloxone Hydrochloride","moa":"Mu Opoid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Harm Reduction Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Purdue Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Harm Reduction Therapeutics \/ Purdue Pharma"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Naloxone Hydrochloride","moa":"Mu opoid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Harm Reduction Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opoid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Harm Reduction Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Harm Reduction Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Harm Reduction Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Purdue Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Naloxone Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Harm Reduction Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.029999999999999999,"dosageForm":"Spray","sponsorNew":"Harm Reduction Therapeutics \/ Purdue Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Harm Reduction Therapeutics \/ Purdue Pharma"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Naloxone Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Harm Reduction Therapeutics \/ Harm Reduction Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Harm Reduction Therapeutics \/ Harm Reduction Therapeutics"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Harm Reduction Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Harm Reduction Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Harm Reduction Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Harm Reduction Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Harm Reduction Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Harm Reduction Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Harm Reduction Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : RiVive (naloxone HCl nasal spray) is an FDA approved, over-the-counter (OTC) medication which is indicated for the emergency treatment of opioid overdose.

                          Brand Name : RiVive

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 20, 2023

                          Lead Product(s) : Naloxone Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : RiVive (naloxone HCl) is a μ opioid receptor antagonist. It is an FDA-approved, over-the-counter medication approved for the emergency treatment of opioid overdose.

                          Brand Name : RiVive

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 20, 2023

                          Lead Product(s) : Naloxone Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : RiVive™ (Naloxone HCl Nasal Spray 3 mg) an opioid antagonist to be available over the counter (OTC) for the emergency treatment of life-threatening opioid overdose.

                          Brand Name : Rivive

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 01, 2023

                          Lead Product(s) : Naloxone Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under the agreement, Catalent will manufacture Harm Reduction Therapeutics’ naloxone nasal spray, RiVive™, for the emergency treatment of known or suspected opioid overdose.

                          Brand Name : Rivive

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 23, 2023

                          Lead Product(s) : Naloxone Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Recipient : Catalent Pharma Solutions

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The proceeds will be used to fund commercial readiness for HRT’s low-cost over-the-counter (OTC) intranasal naloxone spray, tradename RiVive. Naloxone is an opioid antagonist rescue medication used to reverse the effects of a life-threatening opioid ov...

                          Brand Name : Rivive

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 21, 2023

                          Lead Product(s) : Naloxone Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Purdue Pharma

                          Deal Size : $29.9 million

                          Deal Type : Financing

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : RiVive is an intranasal formulation of naloxone (3.0 mg) delivered as an atomized spray (0.1 ml) using a standard unit dose system for single administration.

                          Brand Name : RiVive

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 26, 2022

                          Lead Product(s) : Naloxone Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Revive (naloxone hydrochloride) is a safe and effective opioid antagonist, originally approved by the FDA in 1971 and has been used for decades by both medical professionals and the lay public to successfully reverse opioid overdoses.

                          Brand Name : Revive

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 11, 2022

                          Lead Product(s) : Naloxone Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under its terms, the contract manufacturer will produce Harm Reduction Therapeutics' nasal spray, RiVive™ (3.0mg naloxone), for the emergency treatment of known or suspected opioid overdose.

                          Brand Name : Revive

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 11, 2022

                          Lead Product(s) : Naloxone Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          09

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The additional funding approved today will help HRT continue its work toward making OTC naloxone nasal spray available to the public. HRT plans to file a New Drug Application for naloxone nasal spray with FDA in 2022.

                          Brand Name : Revive

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 23, 2022

                          Lead Product(s) : Naloxone Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Sponsor : Purdue Pharma

                          Deal Size : $17.5 million

                          Deal Type : Financing

                          blank

                          10

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : HRT001 is an intranasal formulation of naloxone (3.0 mg) delivered as an atomized spray (0.1 ml) using a standard unit dose system for single administration. Its tentatively approved tradename is RiVive™.

                          Brand Name : RiVive

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 01, 2022

                          Lead Product(s) : Naloxone Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Sponsor : Sage Chemical

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank